These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 15124243

  • 1. Criteria for improvement in rheumatoid arthritis: alternatives to the American College of Rheumatology 20.
    Albert DA, Huang G, Dubrow G, Brensinger CM, Berlin JA, Williams HJ.
    J Rheumatol; 2004 May; 31(5):856-66. PubMed ID: 15124243
    [Abstract] [Full Text] [Related]

  • 2. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
    Pincus T, Amara I, Koch GG.
    Arthritis Rheum; 2005 Apr; 52(4):1031-6. PubMed ID: 15818698
    [Abstract] [Full Text] [Related]

  • 3. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response.
    American College of Rheumatology Committee to Reevaluate Improvement Criteria.
    Arthritis Rheum; 2007 Mar 15; 57(2):193-202. PubMed ID: 17330293
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. American College of Rheumatology criteria for improvement in rheumatoid arthritis should only be calculated from scores that decrease on improvement.
    Boers M, Verhoeven AC, van der Linden S.
    Arthritis Rheum; 2001 May 15; 44(5):1052-5. PubMed ID: 11352236
    [Abstract] [Full Text] [Related]

  • 6. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA, Bingham CO.
    Semin Arthritis Rheum; 2005 Dec 15; 35(3):185-96. PubMed ID: 16325659
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, Cohen S, Felson D.
    Arthritis Rheum; 2003 Mar 15; 48(3):625-30. PubMed ID: 12632413
    [Abstract] [Full Text] [Related]

  • 9. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
    Anderson JJ, Bolognese JA, Felson DT.
    Arthritis Rheum; 2003 Nov 15; 48(11):3031-8. PubMed ID: 14613263
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M.
    Clin Ther; 2009 Aug 15; 31(8):1754-64. PubMed ID: 19808134
    [Abstract] [Full Text] [Related]

  • 11. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
    Anderson JJ, Wells G, Verhoeven AC, Felson DT.
    Arthritis Rheum; 2000 Jan 15; 43(1):22-9. PubMed ID: 10643696
    [Abstract] [Full Text] [Related]

  • 12. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials.
    Pham B, Cranney A, Boers M, Verhoeven AC, Wells G, Tugwell P.
    J Rheumatol; 1999 Mar 15; 26(3):712-6. PubMed ID: 10090188
    [Abstract] [Full Text] [Related]

  • 13. Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort.
    Kahn KL, Maclean CH, Wong AL, Rubenstein LZ, Liu H, Fitzpatrick DM, Harker JO, Chen WP, Traina SB, Mittman BS, Hahn BH, Paulus HE.
    Arthritis Rheum; 2007 Jun 15; 57(5):707-15. PubMed ID: 17530663
    [Abstract] [Full Text] [Related]

  • 14. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
    Sokka T, Pincus T.
    J Rheumatol; 2003 Jun 15; 30(6):1138-46. PubMed ID: 12784382
    [Abstract] [Full Text] [Related]

  • 15. Effects of clarithromycin in patients with active rheumatoid arthritis.
    Ogrendik M.
    Curr Med Res Opin; 2007 Mar 15; 23(3):515-22. PubMed ID: 17355733
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic accuracy of ACR/EULAR 2010 criteria for rheumatoid arthritis in a 2-year cohort.
    Varache S, Cornec D, Morvan J, Devauchelle-Pensec V, Berthelot JM, Le Henaff-Bourhis C, Hoang S, Thorel JB, Martin A, Chalès G, Nowak E, Jousse-Joulin S, Youinou P, Saraux A.
    J Rheumatol; 2011 Jul 15; 38(7):1250-7. PubMed ID: 21572146
    [Abstract] [Full Text] [Related]

  • 17. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology.
    van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, Wells G, Lange ML, Felson DT.
    J Rheumatol; 1999 Mar 15; 26(3):705-11. PubMed ID: 10090187
    [Abstract] [Full Text] [Related]

  • 18. Response criteria for rheumatoid arthritis in clinical practice: how useful are they?
    Gülfe A, Geborek P, Saxne T.
    Ann Rheum Dis; 2005 Aug 15; 64(8):1186-9. PubMed ID: 15760931
    [Abstract] [Full Text] [Related]

  • 19. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
    Kristensen LE, Saxne T, Geborek P.
    Arthritis Rheum; 2006 Feb 15; 54(2):600-6. PubMed ID: 16447237
    [Abstract] [Full Text] [Related]

  • 20. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P, Levine M, Gaebel K, Thabane L.
    Can J Clin Pharmacol; 2005 Feb 15; 12(3):e254-63. PubMed ID: 16278497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.